August 26, 2025

A Global Calling for Universal Levodopa Access in Parkinson Disease Treatment: Michael S. Okun, MD

The director of the Norman Fixel Institute for Neurological Diseases at UF Health highlighted the need for equitable, worldwide access to levodopa for patients with Parkinson disease. [WATCH TIME: 6 minutes]

August 25, 2025

Supplementary motor area microstructure defines the extent of gait impairment in Parkinson’s disease – Nature

August 25, 2025

Novel in situ seeding immunodetection assay uncovers neuronal-driven alpha-synuclein seeding in Parkinson’s disease – Nature

August 25, 2025

Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson’s Disease under 505(b)(2) NDA Pathway – GlobeNewswire

August 25, 2025

Clinical Insights on Dyskinesia and Tremor in Parkinson’s Disease

Panelists discuss how distinguishing between dyskinesia (choreoform, dance-like movements) and tremor in Parkinson’s disease is crucial for treatment decisions, as modern therapeutic options including extended-release amantadine, continuous subcutaneous delivery systems, and advanced formulations can now effectively manage both motor fluctuations and troublesome dyskinesias simultaneously.